215 related articles for article (PubMed ID: 16487916)
1. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors.
Tonstad S
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):156-62. PubMed ID: 16487916
[TBL] [Abstract][Full Text] [Related]
2. [Positive influence on cardiovascular risk factor by blocking the endocannabinoid system].
Chatterjee T; Ritz A; Ince H; Nienaber ChA; Rehders TC
Praxis (Bern 1994); 2008 May; 97(11):613-21. PubMed ID: 18592956
[TBL] [Abstract][Full Text] [Related]
3. Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors.
Cox SL
Drugs Today (Barc); 2005 Aug; 41(8):499-508. PubMed ID: 16234873
[TBL] [Abstract][Full Text] [Related]
4. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.
Gelfand EV; Cannon CP
J Am Coll Cardiol; 2006 May; 47(10):1919-26. PubMed ID: 16697306
[TBL] [Abstract][Full Text] [Related]
5. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
Hollander P
Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
[TBL] [Abstract][Full Text] [Related]
6. Rimonabant: endocannabinoid inhibition for the metabolic syndrome.
Wierzbicki AS
Int J Clin Pract; 2006 Dec; 60(12):1697-706. PubMed ID: 17109677
[TBL] [Abstract][Full Text] [Related]
7. Modification of cardiometabolic risk through cannabinoid type-1 receptor antagonism.
Andrikopoulos GK; Tzeis S
Angiology; 2008; 59(2 Suppl):44S-8S. PubMed ID: 18635590
[TBL] [Abstract][Full Text] [Related]
8. Rimonabant for treating tobacco dependence.
Steinberg MB; Foulds J
Vasc Health Risk Manag; 2007; 3(3):307-11. PubMed ID: 17703638
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
[TBL] [Abstract][Full Text] [Related]
10. Novel therapies for cardiometabolic risk reduction and implications for clinical practice.
Watson KE
Rev Cardiovasc Med; 2007; 8 Suppl 4():S37-42. PubMed ID: 17934393
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O;
Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461
[TBL] [Abstract][Full Text] [Related]
12. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Scheen AJ
J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
[TBL] [Abstract][Full Text] [Related]
13. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.
Gelfand EV; Cannon CP
Expert Opin Investig Drugs; 2006 Mar; 15(3):307-15. PubMed ID: 16503766
[TBL] [Abstract][Full Text] [Related]
14. Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna.
Cardiovasc J Afr; 2007; 18(5):336-7. PubMed ID: 17985035
[No Abstract] [Full Text] [Related]
15. [Pharmacology of cannabinoid receptors].
Le Fur G; Rinaldi-Carmona M; Barth F; Alexander J
Bull Acad Natl Med; 2007; 191(4-5):933-8; discussion 938-40. PubMed ID: 18225447
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential.
Steinberg BA; Cannon CP
Am J Cardiol; 2007 Dec; 100(12A):27P-32P. PubMed ID: 18154743
[TBL] [Abstract][Full Text] [Related]
17. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.
Kakafika AI; Mikhailidis DP; Karagiannis A; Athyros VG
J Clin Pharmacol; 2007 May; 47(5):642-52. PubMed ID: 17392496
[TBL] [Abstract][Full Text] [Related]
18. The endocannabinoid system as a novel approach for managing obesity.
Lillo JL
J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic effects of rimonabant: clinical implications.
Després JP
Curr Pharm Des; 2009; 15(5):553-70. PubMed ID: 19199981
[TBL] [Abstract][Full Text] [Related]
20. What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management?
Jensen MD
Am J Med; 2007 Sep; 120(9 Suppl 1):S25-31; discussion S31-2. PubMed ID: 17720358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]